Akero Therapeutics Terminates Material Agreement
| Field | Detail |
|---|---|
| Company | Akero Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $37.6 million, $150 million, $35 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Akero just terminated a big deal, what gives?
AI Summary
Akero Therapeutics, Inc. announced on September 23, 2025, the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the agreement, but it is a significant event requiring disclosure.
Why It Matters
The termination of a material definitive agreement can signal a significant shift in business relationships or strategic direction for Akero Therapeutics, potentially impacting its operations and future plans.
Risk Assessment
Risk Level: medium — Termination of a material agreement can indicate underlying issues or strategic changes that may affect the company's financial health and operational stability.
Key Players & Entities
- Akero Therapeutics, Inc. (company) — Registrant
- September 23, 2025 (date) — Date of earliest event reported
- 601 Gateway Boulevard, Suite 350 (address) — Principal executive offices
- South San Francisco, CA 94080 (address) — Principal executive offices
FAQ
What was the material definitive agreement that was terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the name of the other party involved in the terminated agreement.
What is the effective date of the termination?
The earliest event reported is September 23, 2025, which is the date of the termination.
Does this termination have any financial implications for Akero Therapeutics?
The filing does not provide specific details on the financial implications of the termination.
Why did Akero Therapeutics terminate this agreement?
The reasons for the termination of the material definitive agreement are not disclosed in this filing.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-29 16:05:17
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AKRO The Nasdaq Global Se
- $37.6 million — est, fees, costs and expenses, equal to $37.6 million in the aggregate (the "Payoff Amount"),
- $150 million — h aggregate maximum borrowings of up to $150 million (the "Term Loan"). Under the Loan Agree
- $35 million — he Loan Agreement, the Company borrowed $35 million. The Term Loan bore interest at a varia
Filing Documents
- d942538d8k.htm (8-K) — 23KB
- 0001193125-25-223188.txt ( ) — 134KB
- akro-20250923.xsd (EX-101.SCH) — 3KB
- akro-20250923_lab.xml (EX-101.LAB) — 18KB
- akro-20250923_pre.xml (EX-101.PRE) — 11KB
- d942538d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 29, 2025 AKERO THERAPEUTICS, INC. By: /s/ Andrew Cheng Name: Title: Andrew Cheng, M.D., Ph.D. President and Chief Executive Officer